PUBLISHER: DelveInsight | PRODUCT CODE: 1340031
PUBLISHER: DelveInsight | PRODUCT CODE: 1340031
DelveInsight's "Allergic Rhinitis (AR)- Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the Allergic Rhinitis, historical and forecasted epidemiology as well as the Allergic Rhinitis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Allergic Rhinitis (AR) market report provides current treatment practices, emerging drug, market size and market share of the individual therapies, current and forecasted 7MM from 2019 to 2032. The report also covers current Allergic Rhinitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
Allergic rhinitis (AR) is an atopic disease presenting symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. This activity describes the evaluation and treatment of allergic rhinitis and highlights the role of the inter-professional team in improving care for patients with this condition.
The most common diagnostic tests for allergic rhinitis are the percutaneous skin test and the allergen-specific immunoglobulin E (IgE) antibody test. Less common diagnostic tools include nasal provocation testing, nasal cytology (e.g., blown secretions, scraping, lavage, biopsy), naso-laryngoscopy, and intradermal skin testing.
Further details related to country-based variations are provided in the report.
The treatment goal for allergic rhinitis is to relieve symptoms. Therapeutic options to achieve this goal include avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays; leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. ,
Therapies approved in the 7MM include XOLAIR by Novartis Pharmaceuticals (Japan), ODACTRA/ACARIZAX/MITICURE (SLIT-tablet) by ALK-Abello, GRASTEK/GRAZAX (Grass pollen allergy vaccine tablet) by ALK-Abello, ITULAZAX, RAGWITEK/RAGWIZAX, CEDARCURE by ALK-Abello, Stallergenes Greer's ACTAIR (STG320) and ORALAIR, Glenmark Pharmaceuticals' (RYALTRIS), BILAXTEN/BILANOA by FAES Farma/Taiho Pharmaceutical, RUPAFIN by Mitsubishi Tanabe Pharma Corporation, DESALEX by Kyorin Pharmaceutical Co, and ALLESAGA TAPE by Hisamitsu Pharmaceutical Co., Inc.
A high unmet need prevails in the current therapies for treating allergic rhinitis. Despite good efficacy, some patients discontinue or reject SLIT because the treatment has a slow onset, and has no surveillance like SCIT. Poor compliance is a general challenge for prolonged medical treatments.
To cater to their needs, many molecules are in the pipeline to treat allergic rhinitis patients across the 7MM. Some major products are anticipated to hit the market during 2019-2032, including REGN5713-5714-5715 and Grass MATA.
As the market is derived using a patient-based model, the Allergic Rhinitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total prevalent cases of Allergic Rhinitis, Total diagnosed prevalent cases of Allergic Rhinitis, Age-specific diagnosed prevalent cases of Allergic Rhinitis, Severity-specific diagnosed prevalent cases of Allergic Rhinitis, and Allergen-specific diagnosed prevalent cases of Allergic Rhinitis in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032.
The drug chapter segment of the Allergic Rhinitis report encloses a detailed analysis of Allergic Rhinitis late-stage and mid-stage (Phase-III and Phase-II) pipeline drug. It also helps to understand the Allergic Rhinitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
REGN5713-5714-5715 is an investigational combination of three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by the allergen Betv1, which is the main allergen responsible for birch pollen allergies. Birch allergy can trigger reactions such as allergic rhinitis and asthma. The Bet v1-specific mAbs (REGN5713, REGN5714, and REGN5715) were generated using Regeneron's VelocImmune platform. Preclinical studies demonstrated that the three mAbs bind independently and non-competitively to Bet v 1. All three together provided maximal inhibition of Bet v 1 binding to human polyclonal IgE and potently blocked basophil activation ex vivo and mast cell degranulation in vivo.
Grass MATA MPL contains an extract of 13 grass pollens modified with glutaraldehyde to form allergoids that reduce the reactivity with immunoglobulin E (IgE) antibodies without a reduction in other important immunological properties, such as T-cell reactivity. The allergoid is adsorbed to microcrystalline tyrosine as a depot adjuvant system formulation. Monophosphoryl lipid-A (MPL) is included as an adjuvant to increase the immunogenic effect of the immunotherapy and to enhance the switch from an allergen-specific helper T-cell Type 2 (Th2) to helper T-cell Type 1 (Th1) like an immune response.
Detailed emerging therapies list will be provided in the final report.
The management of AR involves allergen avoidance, pharmacotherapy, allergen-specific immunotherapy, or a combination of all three. Pharmacologic options include intranasal corticosteroids (INSs), oral and intranasal antihistamines, intranasal chromones, oral and intranasal decongestants, oral and intranasal anticholinergic agents, and anti-leukotrienes.
Antihistamines, work well for treating allergy symptoms. They may be used when symptoms do not happen often or do not last long. Antihistamine nasal sprays work well for treating AR.
Corticosteroids: Nasal corticosteroid sprays are the most effective treatment for AR. They work best when used nonstop, but they can also be helpful for shorter periods. They can even help when used intermittently. Corticosteroid sprays are generally safe for children and adults. It must be noted that many brands are available in this treatment space, both off-label and prescription based.
Decongestants may also help reduce symptoms such as nasal stuffiness.
Other medicines include: Leukotriene inhibitors are prescription medicines that block leukotriene. These are the chemicals the body releases in response to an allergen that also triggers symptoms.
Allergy Shots (immunotherapy) includes regular shots of the pollen you are allergic to. Each dose is slightly larger than the dose before it until you reach the dose that helps control your symptoms. Allergy shots may help your body adjust to the pollen causing the reaction.
Immunotherapy with allergens has proven efficacy in the treatment of AR/asthma and allergy.
Therapies that have been approved in the 7MM, including XOLAIR by Novartis Pharmaceuticals (Japan), ODACTRA/ACARIZAX/MITICURE (SLIT-tablet) by ALK-Abello, GRASTEK/GRAZAX (Grass pollen allergy vaccine tablet) by ALK-Abello, ITULAZAX, RAGWITEK/RAGWIZAX, CEDARCURE by ALK-Abello, Stallergenes Greer's ACTAIR (STG320) and ORALAIR, Glenmark Pharmaceuticals' (RYALTRIS), BILAXTEN/BILANOA by FAES Farma/Taiho Pharmaceutical, RUPAFIN by Mitsubishi Tanabe Pharma Corporation, DESALEX by Kyorin Pharmaceutical Co, and ALLESAGA TAPE by Hisamitsu Pharmaceutical Co., Inc.(Japan)
In light of the above, some developmental initiatives have been taken toward the management of AR. The condition may evolve as some interesting therapies are heading down the pipeline. This would encourage reimbursement scenarios, doctors' adoption, and patient compliance. Some companies have initiated clinical trials investigating new treatment options, including Regeneron Pharmaceuticals' REGN5713-5714-5715 and Grass MATA by Allergy Therapeutics as the potential therapies lined up for forecast in the 7MM in the DelveInsight therapeutics market model.
This section focuses on the rate of uptake of the potential drug expected to get launched in the market during the study period 2019-2032. For example, we estimate that both drug (REGN5713-5714-5715 and Grass MATA) are expected to be launched in the year 2024 and 2026 in the US, respectively. Both drug are under development in the Phase III stage.
The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers detailed information on collaborations, acquisition and merger, licensing, and patent details for allergic rhinitis emerging therapies.
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on allergic rhinitis evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, drug uptake along with challenges related to accessibility, include the Division of Allergy and Immunology at the University of California in Irvine, USA; Division of Allergy, Immunology, and Rheumatology, Georgetown University Medical School, USA; Allergy Center, Department of Dermatology and Allergy, Berlin, Germany; University Paris-Saclay, France; Centre for Biomedical Investigation Network on Respiratory Diseases (CibeRes), Barcelona, Spain; Graduate School of Medicine, Chiba University, Japan, and Others.
DelveInsight's analysts connected with 50+ KOLs to gather insights, however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the Department of Allergy, Department of Immunology, etc. were contacted. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or allergic rhinitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis is done to analyze multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial's primary and secondary outcome measures are evaluated.
Further, the safety of the drug is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.